All
FDA Approves Braftovi and Mektovi for Some Patients with Metastatic NSCLC
October 12th 2023Braftovi (encorafenib) with Mektovi (binimetinib) has been approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, the agency announced on Wednesday evening.